Ars Technica Follow Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% Markers released top-line results today after previously reporting the trial succeeded. https://arstechnica.com/health/2026/10/personalized-mrna-cancer-vaccine-cut-melanoma-death-recurrence-by-42/ arstechnica.com
